CASE is proud to celebrate this landmark achievement from our member state, Virginia!
British AstraZeneca plc will make its largest single manufacturing investment in the world right here in the Commonwealth of Virginia — part of a record-breaking $50 billion U.S. investment in medicine manufacturing and R&D by 2030.
The new state-of-the-art drug substance manufacturing center will harness AI, automation, and advanced analytics to deliver next-generation medicines for weight management and metabolic health. The project will create hundreds of highly skilled jobs and strengthen America’s domestic pharmaceutical supply chain. This transformational investment underscores Virginia’s leadership in advanced manufacturing, innovation, and workforce excellence and the strength of transatlantic partnerships between the United Kingdom and the United States. Congratulations to Virginia!
Photo ©: Astra Zeneca PLC, UK
More Posts
Weidmüller Group Bolsters U.S. Manufacturing with $16.4m Expansion in Virginia, adding over 100 jobs
